[go: up one dir, main page]

NO20063826L - Sammensetninger omfattende HIV-proteaseinhibitor og cytokrom P450 enzymaktivitetsinhibitor - Google Patents

Sammensetninger omfattende HIV-proteaseinhibitor og cytokrom P450 enzymaktivitetsinhibitor

Info

Publication number
NO20063826L
NO20063826L NO20063826A NO20063826A NO20063826L NO 20063826 L NO20063826 L NO 20063826L NO 20063826 A NO20063826 A NO 20063826A NO 20063826 A NO20063826 A NO 20063826A NO 20063826 L NO20063826 L NO 20063826L
Authority
NO
Norway
Prior art keywords
cytochrome
hiv protease
inhibitor
compositions
enzyme activity
Prior art date
Application number
NO20063826A
Other languages
English (en)
Inventor
Jonathan Quoc Tran
Evan Burr Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20063826L publication Critical patent/NO20063826L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Det beskrives fremgangsmåter for å forbedre farmakokinetikken for visse forbindelser som er nyttige som inhibitorer av HIV proteaseenzymet ved inhibering av enzymaktiviteten av cytokrom P450. Det beskrives videre preparater omfattende visse forbindelser som er nyttige som inhibitorer av HIV proteaseenzymet og minst et middel som inhiberer enzymaktiviteten av cytokrom P450.
NO20063826A 2004-01-30 2006-08-28 Sammensetninger omfattende HIV-proteaseinhibitor og cytokrom P450 enzymaktivitetsinhibitor NO20063826L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54074604P 2004-01-30 2004-01-30
US61499704P 2004-10-01 2004-10-01
PCT/IB2005/000110 WO2005082364A1 (en) 2004-01-30 2005-01-17 Compositions comprising hiv protease inhibitor and cytochrome p450 enzyme activity inhibitor

Publications (1)

Publication Number Publication Date
NO20063826L true NO20063826L (no) 2006-10-24

Family

ID=34915539

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063826A NO20063826L (no) 2004-01-30 2006-08-28 Sammensetninger omfattende HIV-proteaseinhibitor og cytokrom P450 enzymaktivitetsinhibitor

Country Status (15)

Country Link
US (1) US20050171037A1 (no)
EP (1) EP1713478A1 (no)
JP (1) JP2007519706A (no)
KR (1) KR20060127939A (no)
AR (1) AR047584A1 (no)
AU (1) AU2005216712A1 (no)
BR (1) BRPI0506498A (no)
CA (1) CA2555173A1 (no)
CO (1) CO5700739A2 (no)
IL (1) IL176675A0 (no)
MX (1) MXPA06008598A (no)
NO (1) NO20063826L (no)
RU (1) RU2006127429A (no)
TW (1) TW200530204A (no)
WO (1) WO2005082364A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110207660A1 (en) * 2008-08-07 2011-08-25 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
RU2660438C1 (ru) * 2014-07-18 2018-07-06 Джей ДаблЮ ФАРМАСЬЮТИКАЛ КОРПОРЭЙШН Новая соль тенофовира дизопроксила
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
KR100187613B1 (ko) * 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테이제 억제 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
NZ514466A (en) * 1999-04-07 2004-10-29 Pfizer Prod Inc Use of CYP2D6 inhibitors in combination therapies
US20020198160A1 (en) * 2001-05-01 2002-12-26 Everitt Elizabeth A. Compositions and methods for enhancing the bioavailability of pharmaceutical agents
HN2002000136A (es) * 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
US7169932B2 (en) * 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
US7094909B2 (en) * 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
WO2005026114A1 (en) * 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses

Also Published As

Publication number Publication date
JP2007519706A (ja) 2007-07-19
EP1713478A1 (en) 2006-10-25
RU2006127429A (ru) 2008-02-10
CO5700739A2 (es) 2006-11-30
MXPA06008598A (es) 2006-08-28
TW200530204A (en) 2005-09-16
CA2555173A1 (en) 2005-09-09
IL176675A0 (en) 2006-10-31
US20050171037A1 (en) 2005-08-04
AR047584A1 (es) 2006-01-25
BRPI0506498A (pt) 2007-02-13
WO2005082364A1 (en) 2005-09-09
AU2005216712A1 (en) 2005-09-09
KR20060127939A (ko) 2006-12-13

Similar Documents

Publication Publication Date Title
WO2008027932A3 (en) Cytochrome p450 oxidase inhibitors and uses thereof
WO2006020767A3 (en) Thiazole based inhibitors of atp-utilizing enzymes
NO20064358L (no) Svovelforbindelser som inhibitorer for hepatitt C-virum-NS3-serinprotease
WO2005086898A3 (en) Inhibitors of histone deacetylase
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
WO2006071762A3 (en) Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods
WO2008076427A3 (en) Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2007025090A3 (en) Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2007098352A3 (en) Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
NO20080785L (no) Behandling av kreft
NO20064356L (no) Forbindelser som inhibitorer for hepatitt C-virun-NS3-erinprotease
WO2008016883A3 (en) Inhibitors of plasma kallikrein
WO2007067836A3 (en) Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
WO2006110656A3 (en) Compounds, compositions and methods for the treatment of viral infections and other medical disorders
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20083216L (no) Myke proteaseinhibitorer og pro-myke former derav
ATE502997T1 (de) Oberflächenaktive peroxycarbonsäurezusammensetzungen
WO2006087206A3 (en) Androgen receptor-dependent gene expression control by inhibiting the amine oxidase activity of lysine-specific demethylase (lsd1)
EP1993820A4 (en) NEW COMPOUNDS USEFUL FOR IMPROVING PHARMACOKINETICS
NO20091353L (no) Serine hydrolaseinhibitorer
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
ATE529531T1 (de) Gm3-synthase als therapeutisches ziel bei mikrovaskulären komplikationen des diabetes
WO2009051223A1 (ja) 白内障処置のための医薬組成物

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application